| |
 |
      
|
VGX Approach for Universal Flu Vaccine
| |
DNA vaccine targeting
variable influenza HA: [H1, H2, H3, and H5 (Avian)] along with
Conserved Regions of NA and M2e-NP. |
|
| |
All constructs are made using SynCon™
technology |
| |
Proof of Concept Studies completed showing
immunogenecity and protection against H1 and H5 Viruses in Animal
Models. |
| |
Potential for long-term immunity |
| |
Pre-set vaccine regimens for all times |
VGX-3400 Flu Vaccine: Proof of Concept
Against Avian Flu (H5N1)
| |
SynCon™ DNA
Vaccines for Avian Flu (H5N1) – HA, NA, M1, M2-eNP |
| |
Study Design: |
|
|
Mice (10/group) immunized with
10 µg DNA at wk 0, 2, 4 and with 25 µg DNA at wk
8 |
|
|
Animals challenged with aerosolized
lethal dose of Vietnam strain of Avian H5 virus |
VGX-3400 (H5N1) Pre-IND Updates
| |
Efficacy Data in
Animal Models |
|
|
- Strong Neutralizing Antibody
Responses in 5 Separate Preclinical Species
 |
|
|
- Strong CD8+ T cell Responses |
| |
IND-enabling Toxicity Testing
in Animals Completed |
| |
cGMP Manufacturing of Phase I
Clinical Product |
|
|
- Conducted at VGX manufacturing
facility in TX |
|
|
|
